Chapter 4 140 In addition, in the validation cohort, progression-free survival (PFS) was significantly longer in PD-1T signature high patients (median 8.3 months) versus PD-1T signature low patients (median 1.8 months) with HR 0.36 (95% CI: 0.18-0.69), P<0.001. The median overall survival (OS) was 7.0 months versus 5.6 months, respectively, with HR 0.34 (95% CI: 0.17-0.68), P<0.001 (Fig. 3D,E).
RkJQdWJsaXNoZXIy MTk4NDMw